Item 8.01 Other Material Event
May 5, 2022, Odyssey Health, Inc. (OTC:ODYY), f/k/a Odyssey Group International,
Inc., a company focused on developing unique, life-saving medical products,
announced positive results from the first group of patients dosed with PRV-002,
in their Phase I clinical trial. Odyssey’s trial is administering PRV-002, their
novel drug to treat concussion, to healthy human subjects.
Item 7.01 Regulation FD Disclosure
Attached is a copy of a press release being issued by the Company relating to
the above-referenced matter, a copy of which is attached as Exhibit as 99.1 and
is hereby incorporated.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Number Exhibit
99.1 Press Release
104 Cover Page Interactive Data File (embedded within the Inline XBRL
document)
© Edgar Online, source Glimpses
postbrexitcompliance.com 